Xilio Therapeutics stockholders elect three Class II directors, ratify Ernst & Young as auditor

Xilio Therapeutics, Inc.

Daniel Curran, Robert Ross, and Yuan Xu elected as Class II directors for three-year terms through 2026.
Ratification of Ernst & Young as independent auditor for FY 2023: 21,955,354 for, 1,623 against, 230,537 abstain.
Broker non-votes of 3,812,216 recorded on each director election.
Annual meeting held June 8, 2023; all proposals passed with strong support.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Xilio Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Xilio Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

1. The Company’s stockholders elected Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified.

View on SEC.gov

Browse all shareholder votes →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-011031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.